Home-use Erchonia EVRL laser for temporary relief of idiopathic peripheral neuropathy foot pain

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-arm, prospective, active-treatment study in which all enrolled participants will self-administer the Erchonia EVRL device at home. The protocol targets adults over age 22 with a recent diagnosis of idiopathic peripheral neuropathy and at least three months of constant foot pain. Participants must be on a stable analgesic regimen and agree to avoid other non-study foot pain therapies during the study. Outcomes will measure temporary pain relief following prescribed home use of the active device.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Previously diagnosed with idiopathic peripheral neuropathy by a suitably qualified and licensed health professional within the past 6 months.
* Over the age of 22 years of age
* Able to read and write English
* Constant feet pain on-going over at least the past 3 months
* Subjects using analgesics (pain medication) must be on a stable analgesic regimen (i.e., no changes to the prescribed analgesic regimen) over a period of at least 14 days prior to study enrollment; and be willing and able to not have planned upward dose titration of analgesics during the study period. Decreasing frequency of analgesic use during the study is permitted. Cannabis prescribed for medicinal purposes qualifies as an analgesic in this context
* Willing and able to refrain from engaging in any non-study therapies for the management of foot pain throughout the course of study participation, including conventional therapies such as physical therapy, occupational therapy, hot or cold packs, and alternative therapies such as chiropractic care and acupuncture
* Agrees to refrain from taking a dosage of analgesic (pain medication) for at least 6 hours before a scheduled VAS foot pain rating is to be recorded
* Subject's degree of foot pain on the 0-100 VAS, with "0" being no pain and "100" being worst pain imaginable, is 50 or greater

Exclusion Criteria:

* Diabetic, referred to as having hemoglobin A1c (HbA1C) of 6.5% or higher
* Previously diagnosed with any definitive (i.e. not idiopathic) cause of peripheral neuropathy by a suitably qualified and licensed health professional within the past 6 months, such as diabetes, injury, infection, toxins and poisons, alcoholism, medications such as chemotherapy, autoimmune disorders, etc..
* Pregnant or possibly pregnant, breastfeeding, or planning pregnancy during the intended course of study participation
* Open wounds (sores, cuts, ulcers, etc.) on or around the treatment area on the feet
* Cancerous growths or lesions on or around the treatment area on the feet
* Difficulty with hand dexterity sufficient to negatively impact the ability to administer treatments with the laser such as from severe arthritis in the hands, Multiple Sclerosis, Cerebral Palsy, Parkinson's Disease, Huntington's Disease, etc.

Where it's running

• Franco & Co
  Miramar, Florida, United States Recruiting

Study contacts

• Study coordinator: Travis Sammons
• Email: tsammons@erchonia.com
• Phone: 8882420571

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood microRNA markers for chemotherapy-related peripheral nerve damage in lung and colorectal cancer

  This study will test whether levels of tiny blood molecules called microRNAs can predict how often and how badly patients with lung or colorectal cancer get nerve damage from certain chemotherapies.

  Recruiting University Hospital, Clermont-Ferrand · Clermont-Ferrand · NCT07427537

• Feasibility of paired non-invasive blood flow and tissue oxygen monitoring to detect limb ischemia during lithotomy-position surgeries

  This study tests whether using combined non-invasive blood flow monitoring and tissue oxygen sensors during long lithotomy surgeries can help detect early limb ischemia in adults.

  Recruiting The University of Texas Health Science Center, Houston · Houston, Texas and 1 other locations · NCT07387653

• Using neuromodulation to treat pain from chemotherapy-induced peripheral neuropathy

  This study is testing a new way to relieve pain from nerve damage caused by chemotherapy in patients with lower extremity CIPN.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT06121232

• Electrical stimulation to improve recovery after cubital tunnel surgery

  This study is testing a new electrical stimulation treatment to see if it helps people recover better after surgery for cubital tunnel syndrome.

  Recruiting at 2 sites Epineuron Technologies Inc. · Hamilton, Ontario and 1 other locations · NCT05980767

• Evaluating Ketotifen's protective role against chemotherapy-induced nerve damage

  This study is testing if Ketotifen can help prevent nerve damage caused by chemotherapy in people with stage III colorectal cancer.

  Recruiting Phase 3 Tanta University · Tanta, Other · NCT05624138

• Peripheral nerve block for painful diabetic neuropathy

  This study is testing if a nerve block can help adults with painful diabetic neuropathy feel less pain without stopping their regular medications.

  Recruiting University of Aarhus · Aarhus N, Jutland · NCT04699734

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.